

May 30, 2018



Veru to Present at Jefferies 2018 Global Healthcare Conference on Wednesday, June 6th

MIAMI, May 30, 2018 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a urology and oncology biopharmaceutical company, today announced that the company's Chairman, President and Chief Executive Officer, Mitchell Steiner, M.D., will present at the Jefferies 2018 Global Healthcare Conference at 11:30 am ET on June 6, 2018 at the Grand Hyatt Hotel in New York City.

A webcast of the presentation will be available at www.verupharma.com. Listeners are encouraged to visit the web site at least 10 minutes prior to the start of the presentation to register, download and install any necessary software. The presentation will be archived and accessible on the web site for at least 90 days.

About Veru Inc.

Veru Inc. (Veru) is a urology and oncology biopharmaceutical company. The company is currently developing drug product candidates: Tamsulosin DRS, slow release granules, and Tamsulosin XR capsules for lower urinary tract symptoms of benign prostatic hyperplasia (BPH) (NDA planned 2018), Solifenacin DRG, slow release granules, for overactive bladder (urge incontinence, urgency and frequency of urination) (NDA planned 2019), Tadalafil/finasteride combination capsule for restricted urination because of an enlarged prostate (NDA planned 2019), VERU-944 (cis-clomiphene citrate) for hot flashes in men associated with prostate cancer hormone treatment (planned Phase 2 in 2018), and VERU-111 a novel oral anti-tubulin cancer therapy targeting alpha & beta tubulin for a variety of malignancies, including metastatic prostate, breast, endometrial and ovarian cancers (planned Phase 1/2 in 2018).

To help support these clinical development programs, the company markets and sells the PREBOOST® medicated individual wipe, which is a male genital desensitizing drug product for the prevention of premature ejaculation which is being co-promoted with Timm Medical Technologies, Inc. and the FC2 Female Condom® (now available by prescription in the US including through the virtual doctor smartphone app "HeyDoctor" at www.fc2.us.com) in the United States and through The Female Health Company Division in the Global Public Health Sector. The Female Health Company Division markets to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world. More information about Veru and its products can be found at www.verupharma.com, www.PREBOOST.com, www.fc2.us.com and

www.fc2femalecondom.com. For corporate and investor-related information about the Company, please visit <https://verupharma.com/investors>.

Contact:

Kevin Gilbert 786-322-2213



Source: Veru Inc.